Atopic Dermatitis

Dr Matthew Zirwas describes his experience using JAK inhibitor ruxolitinib in his clinical practice.

The FDA approved the topical JAK1/JAK2 inhibitor ruxolitinib for the treatment of mild to moderate atopic dermatitis in September 2021.

One of the key differences between diagnosing AD in patients with skin of color compared to White skin is erythema.

Click here to answer this week's poll.

The FDA has approved abrocitinib for adult patients with moderate to severe AD.

Clinicians provide insight into the risk of high systemic absorption levels with JAK inhibitor treatments.

AbbVie announces the approval after 3 studies show the efficacy and safety of upadacitinib using mono- and combination therapy.

What new treatments are coming to infectious disease? How can they be prevented and what misconceptions are affecting treatment? Learn about this and more in this video with Ted Rosen, MD.

Ted Rosen, MD, explains the top points of his presentation, "What's Hot and New in Infectious Disease?" from the 2022 Winter Clinical Dermatology Conference.

Treatments awaiting FDA approval could bolster the range of nonsteroids and well-tolerated topicals aimed at combating pediatric cutaneous disorders.

In this video interview, Peter A. Lio, MD, FAAD, expands on his Winter Clinical Dermatology 2022 presentation, "What's Hot and New in Pediatric Dermatology?" He talks the pipeline, black box warnings, and more on atopic dermatitis treatments.

In this video, Peter Lio, MD, FAAD, expands on his presentation at the 19th annual Winter Clinical Dermatology Conference by diving into molluscum contagiousum treatment and the potential of cantharidin 0.7% (VP-102; Verrica).

Skin sensitivity will be a factor in vehicles for new treatments.

Matthew Zirwas, MD, breaks down the safety of JAK inhibitors based on clinical trial data.

The new research will investigate many factors of the skin disease like changes over lifetime, new therapy pathways, and the science behind itch and inflammation.

Key opinion leaders explain the box warnings and safety profiles of JAK inhibitors.

Leo Pharma has announced the FDA approval of tralokinumab-Idrm (Adbry; Leo Pharma) for the treatment of moderate-to-severe atopic dermatitis in adults 18 years or older. Jonathan Silverberg, MD, PhD, MPH, associate professor of Dermatology at George Washington University School of Medicine and Health Sciences, and tralokinumab clinical trial investigator gives his comments on this approval.

Linda Stein Gold, MD, provides an overview of the four JAK inhibitors currently available for treating inflammatory diseases.

Factors ranging from demographics to the COVID-19 pandemic are shifting the landscape of occupational dermatoses.

A recent study investigated practical issues related to the use of dupilumab for atopic dermatitis.

A study in JAMA Dermatology dove into the subject of atopic eczema, investigating the patterns of activity that may continue into adulthood.

Arcutis Biotherapeutics has announced data suggesting that the vehicle in the investigational roflumilast cream had similar moisturizing properties as a commercially marketed, dermatologist-recommended, ceramide-containing moisturizer in adults with mild eczema.

Seborrheic dermatitis will affect roughly half of all infants, making knowing how to treat and manage it key.

In this video interview, James Q Del Rosso, DO, tackles the clinical impact of JAK Inhibitors and how to deal with patient concern.

In this exclusive video interview, James Q Del Rosso, DO, gets into the details of JAK inhibitors, explaining how they work and cutting through the headlines around the treatments.